HDAC3 and non-small cell lung carcinoma: Recent years, HDAC inhibitors have been developed to antagonize the reduced global histone acetylation observed in many tumor types, including NSCLC.69 The combination of HDAC3 inhibitor and trametinib has shown therapeutic benefits in genetically engineered mouse models of NSCLC.